ACLARIS THERAPEUTICS INC
NASDAQ: ACRS (Aclaris Therapeutics, Inc.)
Last update: 3 hours ago6.09
-0.27 (-4.25%)
| Previous Close | 6.36 |
| Open | 6.34 |
| Volume | 2,786,119 |
| Avg. Volume (3M) | 1,767,151 |
| Market Cap | 850,551,808 |
| Price / Sales | 77.17 |
| Price / Book | 5.06 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,222.27% |
| Diluted EPS (TTM) | -1.59 |
| Quarterly Revenue Growth (YOY) | -39.30% |
| Total Debt/Equity (MRQ) | 1.72% |
| Current Ratio (MRQ) | 5.06 |
| Operating Cash Flow (TTM) | -12.32 M |
| Levered Free Cash Flow (TTM) | -52.41 M |
| Return on Assets (TTM) | -18.20% |
| Return on Equity (TTM) | -91.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Aclaris Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -1.50 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.69% |
| % Held by Institutions | 88.24% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KOLBECK ROLAND WILHELM | - | 5.20 | -12,385 | -64,402 |
| Aggregate Net Quantity | -12,385 | |||
| Aggregate Net Value ($) | -64,402 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.20 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KOLBECK ROLAND WILHELM | Officer | 01 Aug 2026 | Disposed (-) | 12,385 | 5.20 | 64,402 |
| KOLBECK ROLAND WILHELM | Officer | 01 Aug 2026 | Option execute | 36,375 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |